
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is currently undervalued with its diverse drug portfolio to drive long-term growth, an expected $2-3 billion in peak annual sales from multiple asset indications, stabilized or low costs due to resolution of CMS Medicaid dispute, the potential for increasing profitability through low priced topical ruxolitinib reducing net revenue pressure, and the recent acquisition of Star Therapeutics expanding the pipeline with high potential assets.
Bears say
Incyte is making strategic acquisitions to expand its hematology franchise and offset the expected impact of the LOE of its leading drug Jakafi. While the acquired drug VGA039 has promising attributes, such as a manageable regulatory path and potential for significant market expansion, there are also conservative elements in the company's guidance. Analysts believe that Incyte's potential peak sales for VGA039 may be underestimated, and a successful launch could lead to upside in stock performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares